Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous muscle-derived stem cell and fibroblast injection for female stress urinary incontinence
IRCT20140911019125N7Phase 2Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Feb 2017
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AMDC-USR and azficel-t in stress urinary incontinence (SUI), sponsored by Kerman University of Medical Sciences. Primary endpoints: Closure pressure, Urinary flow rate and 3 more. Started Feb 2017; status: completed.
02
Drugs
AMDC-USRazficel-t
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on IRCT20140911019125N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140911019125N7.